Beijing, China

Zonggen Peng

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 7.6

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2017-2024

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Zonggen Peng: Innovator in Antiviral Compounds

Introduction

Zonggen Peng is a prominent inventor based in Beijing, China. He has made significant contributions to the field of antiviral compounds, holding a total of 3 patents. His work focuses on developing innovative solutions to combat viral infections, showcasing his expertise and dedication to medical research.

Latest Patents

One of Zonggen Peng's latest patents is titled "Phenylmethyl-piperazine derivatives and antiviral uses thereof." This patent discloses a benzyl piperazine compound, along with its preparation method and application in antiviral treatments. Experimental results demonstrate that this compound exhibits significant antiviral activity, coupled with low cytotoxicity and a high selectivity index. Another notable patent involves a new aromatic cyanogen compound, which also includes a preparation method and its application in antiviral drugs, particularly for anti-HCV treatments.

Career Highlights

Zonggen Peng has worked with esteemed institutions such as the Chinese Academy of Medical Sciences and the Chinese Academy of Sciences. His career is marked by a commitment to advancing antiviral research and developing effective therapeutic agents.

Collaborations

Throughout his career, Zonggen Peng has collaborated with notable colleagues, including Yanping Li and Zhuorong Li. These partnerships have contributed to the success of his research and the development of his patented compounds.

Conclusion

Zonggen Peng's innovative work in antiviral compounds highlights his significant role in medical research. His contributions continue to pave the way for new treatments and advancements in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…